Feature

Accelerating Structure-based Drug Design for Complex Membrane Proteins

Nuclera and leadXpro partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets

  • By

  • March 9, 2026

  • 3 min

Share

A scientific partnership between Nuclera and leadXpro aims to enhance drug discovery through improved membrane protein screening. Combining Nuclera's eProtein Discovery technology with leadXpro's AI and machine learning expertise, this collaboration focuses on overcoming challenges in expressing and purifying membrane proteins necessary for structure-based therapeutic development. The result will be an end-to-end workflow that accelerates insights into membrane proteins, significantly advancing structure-based drug discovery efforts.

Original Source(s)

Accelerating Structure-based Drug Design for Complex Membrane Proteins

Nuclera and leadXpro partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets

  • March 9, 2026

  • 3 min

Related Content

A Pharmacologic Off-Switch for Split CARs

Study describes a venetoclax-regulated off-switch CAR system with dose-dependent control of receptor assembly in vitro and in vivo

  • March 3, 2026

  • 2 min
Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

New Collaboration to Automate Cell Therapy Manufacturing with Robotics

Focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technology

  • February 12, 2026

  • 2 min